Trial Profile
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine group B OMV Novartis (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib vaccine conjugate; Measles and rubella virus vaccine; Measles mumps and rubella virus vaccine; RIX 4414; Varicella zoster virus vaccine live
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms MENB REC 2ND GEN-023(V72_57)
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 26 Feb 2024 Planned End Date changed from 20 Aug 2024 to 8 Oct 2024.
- 26 Feb 2024 Planned primary completion date changed from 20 Aug 2024 to 8 Oct 2024.
- 20 Jul 2023 Status changed from recruiting to active, no longer recruiting.